TechMARK movers: AstraZeneca protects patents

30th Jun 2010 15:14

Anglo-Swedish drugs developer AstraZeneca has lost some of its early gains but it remains well up on the day after a favourable US court ruling in its battle to keep control of the patents to its best-selling cholesterol-lowering drug Crestor.The ruling means that cheaper, generic versions of Astra's blockbuster drug can not enter the US market until 2016.Panmure Gordon has upped its price target from 3300p to 3600p.Yesterday, AstraZeneca spent more than £20m buying back shares at 2955p each. Israeli technology firm Emblaze has admitted that it is abandoning plans to manufacture the First ELSE mobile device. A fortnight ago Emblaze was denying reports that its ELSE mobile project was in trouble.The company says it will concentrate its efforts on licensing the ELSE Intuition platform and technology. This will sharply reduce the company's operational and development costs.Emblaze has lost more than one-quarter of its value over the past month. FTSE TechMARK - RisersRM Group (RM.) 185.00p +9.47%AstraZeneca (AZN) 3,184.50p +8.06%Filtronic (FTC) 28.00p +5.66%Micro Focus International Plc (MCRO) 422.30p +5.15%Sinclair Pharma (SPH) 25.50p +3.92%Torotrak (TRK) 19.75p +3.80%Sepura (SEPU) 42.00p +2.44%NXT (NTX) 11.50p +2.17%GlaxoSmithKline (GSK) 1,143.00p +1.78%Consort Medical (CSRT) 377.00p +1.48%FTSE TechMARK - FallersVislink (VLK) 22.25p -5.62%Emblaze (BLZ) 31.50p -4.55%BATM Advanced (BVC) 22.00p -4.35%Renovo Group (RNVO) 27.00p -3.57%Biocompatibles International (BII) 253.00p -3.25%ProStrakan (PSK) 67.00p -3.25%DRS Data (DRS) 15.50p -3.12%Dialight (DIA) 310.25p -3.05%Phytopharm (PYM) 8.13p -2.98%Parity Group (PTY) 8.50p -2.94%